A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Active-controlled Phase 2 Study to Compare the Efficacy and Safety of s.c. MAA868 Versus s.c. Enoxaparin in Adult Patients Undergoing Unilateral Total Knee Arthroplasty
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs MAA 868 (Primary) ; Enoxaparin sodium
- Indications Thrombosis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 10 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Jul 2018 The trial has been discontinued in Spain.
- 31 Jul 2018 The trial has been discontinued in Austria.